Advertisement
CLNN vs GOSS
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLNN is a StrongBuy and GOSS is a Hold.
Momentum Indicator for CLNN turns positive, indicating new upward trend
CLNN saw its Momentum Indicator move above the 0 level on October 22, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 90 similar instances where the indicator turned positive. In 78 of the 90 cases, the stock moved higher in the following days. The odds of a move higher are at 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CLNN's RSI Indicator exited the oversold zone, 38 of 44 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for CLNN just turned positive on October 21, 2026. Looking at past instances where CLNN's MACD turned positive, the stock continued to rise in 39 of 45 cases over the following month. The odds of a continued upward trend are 87%.
CLNN moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for CLNN crossed bullishly above the 50-day moving average on November 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 71%.
Following a +11.65% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLNN advanced for three days, in 191 of 230 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Aroon Indicator entered an Uptrend today. In 105 of 124 cases where CLNN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 48 cases where CLNN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLNN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
CLNN broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. CLNN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-2.266) is normal, around the industry mean (6.914). P/E Ratio (-1.113) is within average values for comparable stocks, (7.137). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (8.458). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. CLNN's P/S Ratio (222.222) is very high in comparison to the industry average of (5.003).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLNN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
GOSS's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for GOSS turned positive on October 12, 2026. Looking at past instances where GOSS's MACD turned positive, the stock continued to rise in 34 of 38 cases over the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on GOSS as a result. In 60 of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
Following a +9.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where GOSS advanced for three days, in 214 of 252 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GOSS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
GOSS broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for GOSS entered a downward trend on October 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 32 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.636) is normal, around the industry mean (3.498). P/E Ratio (-0.230) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.666) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. GOSS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GOSS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
CLNN | GOSS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 18 | 21 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 95 Overvalued | 32 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 61 | 64 | |
P/E GROWTH RATING 1..100 | 14 | 27 | |
SEASONALITY SCORE 1..100 | 90 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GOSS's Valuation (32) in the Pharmaceuticals Major industry is somewhat better than the same rating for CLNN (95) in the null industry. This means that GOSS’s stock grew somewhat faster than CLNN’s over the last 12 months.
GOSS's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as CLNN (100) in the null industry. This means that GOSS’s stock grew similarly to CLNN’s over the last 12 months.
GOSS's SMR Rating (100) in the Pharmaceuticals Major industry is in the same range as CLNN (100) in the null industry. This means that GOSS’s stock grew similarly to CLNN’s over the last 12 months.
CLNN's Price Growth Rating (61) in the null industry is in the same range as GOSS (64) in the Pharmaceuticals Major industry. This means that CLNN’s stock grew similarly to GOSS’s over the last 12 months.
CLNN's P/E Growth Rating (14) in the null industry is in the same range as GOSS (27) in the Pharmaceuticals Major industry. This means that CLNN’s stock grew similarly to GOSS’s over the last 12 months.
| CLNN | GOSS | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 86% | N/A |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 88% |
| Momentum ODDS (%) | 2 days ago 87% | 2 days ago 76% |
| MACD ODDS (%) | 2 days ago 87% | 4 days ago 89% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 85% |
| TrendMonth ODDS (%) | 2 days ago 83% | 2 days ago 86% |
| Advances ODDS (%) | 5 days ago 83% | 4 days ago 85% |
| Declines ODDS (%) | 2 days ago 90% | 2 days ago 89% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 82% |
| Aroon ODDS (%) | 2 days ago 85% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CLNN’s FA Score shows that 1 FA rating(s) are green while GOSS’s FA Score has 2 green FA rating(s).
- CLNN’s FA Score: 1 green, 4 red.
- GOSS’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CLNN’s TA Score shows that 7 TA indicator(s) are bullish while GOSS’s TA Score has 3 bullish TA indicator(s).
- CLNN’s TA Score: 7 bullish, 3 bearish.
- GOSS’s TA Score: 3 bullish, 4 bearish.
Price Growth
CLNN (@Food: Major Diversified) experienced а -0.76% price change this week, while GOSS (@Biotechnology) price change was +12.28% for the same time period.
The average weekly price growth across all stocks in the @Food: Major Diversified industry was +1.76%. For the same industry, the average monthly price growth was -4.67%, and the average quarterly price growth was -16.15%.
The average weekly price growth across all stocks in the @Biotechnology industry was -3.38%. For the same industry, the average monthly price growth was -5.88%, and the average quarterly price growth was -18.27%.
Reported Earning Dates
CLNN is expected to report earnings on Mar 29, 2027.
GOSS is expected to report earnings on Mar 12, 2027.
Industries' Descriptions
@Food: Major Diversified (+1.76% weekly)Companies in this industry usually make a diverse range of agricultural and/or processed food. Some prominent names in this segment are Mondelez International, which makes chocolates, biscuits, cookies etc. The Kraft Heinz Company specializes in ketchups, sauces, fruit drink pouches and many more. General Mills, Inc. sells flour and cereal. Kellogg is famous for its snacks and breakfast cereal. And so on down the line. As more and more consumers are looking for healthier options in food in recent years, several legacy food companies have responded by revamping brands to include organic and no-added-sugar versions, and/or acquiring healthy food firms, and even streamlining operations.
@Biotechnology (-3.38% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
CLNN and
Correlation & Price change
A.I.dvisor indicates that over the last year, CLNN has been loosely correlated with KYMR. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if CLNN jumps, then KYMR could also see price increases.
| Ticker / NAME | Correlation To CLNN | 1D Price Change % | ||
|---|---|---|---|---|
| CLNN | 100% | -2.00% | ||
| KYMR - CLNN | 36% Loosely correlated | +0.31% | ||
| VERA - CLNN | 35% Loosely correlated | -3.24% | ||
| KZIA - CLNN | 33% Poorly correlated | -4.75% | ||
| GOSS - CLNN | 30% Poorly correlated | -2.40% | ||
| BMRN - CLNN | 30% Poorly correlated | +0.93% | ||
More | ||||
GOSS and
Correlation & Price change
A.I.dvisor indicates that over the last year, GOSS has been loosely correlated with LITS. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if GOSS jumps, then LITS could also see price increases.
| Ticker / NAME | Correlation To GOSS | 1D Price Change % | ||
|---|---|---|---|---|
| GOSS | 100% | -2.40% | ||
| LITS - GOSS | 46% Loosely correlated | -6.64% | ||
| APVO - GOSS | 41% Loosely correlated | -10.00% | ||
| IDYA - GOSS | 38% Loosely correlated | +1.08% | ||
| XNCR - GOSS | 38% Loosely correlated | -2.73% | ||
| SYRE - GOSS | 38% Loosely correlated | +1.06% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| HIBS | 21.80 | 1.14 | +5.52% |
| Direxion Daily S&P 500 High Beta Bear 3X ETF (HIBS) | |||
| DFSI | 45.65 | 0.10 | +0.22% |
| Dimensional International Sustainability Core 1 ETF (DFSI) | |||
| PSDM | 50.14 | 0.02 | +0.04% |
| PGIM Short Duration Multi-Sector Bond ETF (PSDM) | |||
| WDEF | 26.71 | -0.21 | -0.76% |
| WisdomTree Europe Defense Fund (WDEF) | |||
| WYFL | 0.78 | -0.18 | -19.17% |
| Defiance Daily Target 2X Long WYFI ETF (WYFL) | |||